To The Moon

Overview:  Market Performance Shows Mixed Trends The global stock markets have been navigating mixed signals, with inflation concerns easing but economic uncertainties still looming. In the pharmaceutical sector, companies like Eli Lilly (LLY) $Eli Lilly(LLY)$   continue to show robust growth, driven by strategic investments and innovations. Despite broader market volatility, the healthcare sector has remained resilient, benefiting from increased focus on long-term health issues such as Alzheimer's, diabetes, and obesity. Eli Lilly's Bold Expansion in Ireland  Eli Lilly has made significant strides with its latest announcement of two facility expansions in Ireland, totaling a $1.8 billion investmen

Overview: The Market at a Glance The broader market continues to exhibit mixed performance, with tech giants like Apple$Apple(AAPL)$  , Microsoft$Microsoft(MSFT)$  , and Nvidia$NVIDIA Corp(NVDA)$   dominating headlines as they maintain their positions in the trillion-dollar club. Meanwhile, traditional sectors, particularly pharmaceuticals, are catching up, with Eli Lilly $Eli Lilly(LLY)$   emerging as a prime candidate to join this elite group. Driven by the booming weight-loss drug market, Eli Lilly's stock has surged significantly, positioning it as a potential non-tech contender

$Eli Lilly(LLY)$ , with ample cash flow, has made a significant premium acquisition of $Morphic Holding, Inc.(MORF)$ , which has a complementary business outlook. Investment banks have set a target price for $Eli Lilly(LLY)$ above $1040. If one is optimistic about the long-term prospects, it might be worth continuing to hold $Eli Lilly(LLY)$ and consider some call options and selling put options?Below are personal opinion, for discussion purposes only, and I welcome any additional insights from experts.Source:InvestorPlace1.Eli Lilly (LLY) acquires Morphic Holding, Inc. (MORF) at a premium, causing the latter's stock to sur

$Eli Lilly(LLY)$ s Alzheimer's disease new drug donanemab (trade name Kisunla) was approved by the FDA. This is an important breakthrough that provides new treatment options for Alzheimer's disease patients. The stock opened lower that day, not because of the news, but because Biden joined Bernie Sanders in "calling" for $Novo Nordisk (NVO)$'s two Netflix diet pills, Ozempic and Wegovy, have had their prices drastically cut, and Eli Lilly has been hit because of its GLP-1 drug Mounjaro.But it's just shouting, and could be seen as nothing more than a means for Biden, who lost the first debate, to seemingly win favor with American voters. Lilly shares opened lower and higher during the session.C

$Eli Lilly(LLY)$  $Novo-Nordisk A/S(NVO)$   Both overrated. I don't expect any more up side

I'm hesitant to invest in LLY and NVO stocks because I'm not yet familiar with these companies.

Eli Lilly ($Eli Lilly(LLY)$) has been the talk of the town, with its stock soaring a staggering 125% in the past year. As it joins the heavyweight ranks of the S&P 500, rubbing shoulders with tech giants like Nvidia ($NVIDIA Corp(NVDA)$) and Apple ($Apple(AAPL)$), it's clear that Lilly's growth trajectory is turning heads faster than a neck brace at a tennis match. Weighing the Pros and Cons: Financial Performance Breakdown Eli Lilly (LLY) Stock Price Performance (2023-2024) What's fuelling this meteoric rise, you ask? Well, imagine a world where shedding those pesky extra pounds is as easy as pie (but without the calories). Lilly's got a golden goose in the f

TigerGPT Answer: 【Forecast Data】 Eli Lilly and Co (LLY) is forecasted to have an Earnings Per Share (EPS) of $2.46 for Q1 2024. The total revenue estimate is $8,922,458,560, and the EBIT estimate is $2,678,557,290 for the same quarter. Compared to Q1 2023, the EPS has increased by 51.85%, total revenue by 28.15%, and EBIT by 65.42%. These significant increases suggest a strong growth trajectory for the company, reflecting successful product launches, increased demand for its products, or improved operational efficiency. 【Quarterly Important News】 Key news over the past quarter includes: 1. German Chancellor Olaf Scholz's commitment to support the pharmaceutical industry, which could create a favorable environment for Eli Lilly's operations in Germany

Novo Nordisk (NYSE:NVO) has successfully implemented a reduction in its share capital following shareholder approval at its Annual General Meeting on March 21, 2024. The pharmaceutical giant has reduced its B share capital from DKK 343,512,800 to DKK 339,012,800, achieved through the cancellation of 45 million B shares, each with a nominal value of DKK 0.10. This action has decreased the company’s total share capital to DKK 446,500,000, which is now divided into A shares totaling DKK 107,487,200 and B shares at DKK 339,012,800.  Despite the reduction, Novo Nordisk assured stakeholders that the move will not impact its ongoing share repurchase program, which will continue as planned.

Shares of three biotech stocks, $Viking Therapeutics(VKTX)$ $Skye Bioscience Inc.(SKYE)$ $Janux Therapeutics, Inc.(JANX)$, have surged at least 269% so far this year. Do they have room to rise?1.Viking Therapeutics Since $Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$ launched their own weight-loss treatments, both stocks have surged. VKTX is working on a GLP-1 therapeutic oral solution called VK2735. In Phase II trials, VK2735 performed even better than NVO's Wegovy or LLY's Zepbound.VKTX shares are up 269% year-to-date and could rise even higher as VK2735 advances in late-stage tri

1."Miracle Weight Loss Drug" Finds a New Purpose $Eli Lilly(LLY)$ ′s Zepbound,a weight loss drug, is emerging as a potential treatment for sleep apnea, aprevalent disorder linked to serious health risks.This development could be a game−changer,offering a much−needed solution for conditions that affect many,including some of my family.Its worth for us to keep an eye on Zepbound′s clinical progress—it could significantly impact LLY's future prospects. 📈🧪Eli Lilly's weight loss drug Zepbound found to reduce sleep apnea, company says2. If Zepbound proves effective for sleep apnea in trials, it could benefit:Sleep Apnea Patients: 😴 Great news for those seeking new treatments!Obese Patients: 🏋️‍♀️ As a weight loss drug, it might offer a two-for-one thera

My favourite sectors to invest in:• semiconductors• software as a service • payments• credit rating / scores• financial data• healthcareI prefer business facing services, rather than consumer facing products. Revenues are more resilient and predictable. Although I accept Hermes is something special.In healthcare, my favorites are $Novo-Nordisk A/S(NVO)$ $IDEXX Laboratories(IDXX)$ $Genmab A/S(GMAB)$ and $Sartorius AG(SARTF)$ all immediately come to mind.I’m sure AI will cause a lot of disruption. But there are plenty of reasons to invest in semis - AI is just one of them.Any Payments stocks other than

图片In the past 12 months, the stock price of $Eli Lilly(LLY)$ has skyrocketed to triple digits, and the most significant driving force behind this surge is weight loss drugs. The weight loss drug market is poised to become a colossal $100 billion industry, and Eli Lilly's two weight loss drugs, Mounjaro and Zepbound, are both expected to become long-term blockbusters.In the weight loss drug market, Eli Lilly and $Novo-Nordisk A/S(NVO)$ still hold the lion's share. But here's the kicker: Eli Lilly is poised to continue dominating this market in the future.First, Mounjaro was approved to treat type 2 diabetes, but doctors often prescribe it as a weight loss drug, and it brought in more than $5 billion in reven